CytomX Bounces Back From Trial Setback With Regeneron Bispecific Antibody Partnership
Gets $30m Upfront
The US biotech has nabbed a deal with Regeneron to develop bispecific cancer therapies by combining their respective technology platforms, getting $30m upfront in a positive twist of fate following a recent clinical trial challenge.
You may also be interested in...
The gene therapy firm announced that Bristol terminated a collaboration started in 2015. Nona follows its recent alliance with Moderna with a second collaboration, this time with Dragonfly.
The company presented positive early data at ESMO for two bispecific antibodies that are important to the company's long-term business strategy, MUC16xCD3 and METxMET.
Public Company Financings: Theravance sold its 85% interest in Trelegy royalties from GSK and Innoviva sold its 15% interest for up to $1.8bn in total. Also, ProKidney grossed $597m from its SPAC merger, Pliant raised $200m in a post-Phase IIa offering and Marinus earned $110m in a PRV sale.